Egis-rus Pharmaceutical plant Egis

The Egis company is the Hungarian pharmaceutical company, one of the leading pharmaceutical companies in Central and Eastern Europe. Its activity covers all cycle of pharmaceutical production from research and development before production of active substances and finished goods for sale. Now product assortment of Egis company contains more than 500 medicines of different forms and dosages.

History

2015: In Russia the first bioanalogue of medicine for treatment of rheumatoid arthritis will appear

On September 8, 2015 in Seoul (South Korea) the pharmaceutical plant "EGIS Pharmaceuticals" (Hungary), South Korean biopharmaceutical company "Celltrion" and the Russian bifarmatsevtichesky company "Nanolek" signed the document on cooperation according to which Egis starts local production of a bioanalogue infliksimab Flammegis on the Russian production site in the Kirov region. Фламмэгис® the Krone and ulcer colitis is applied to treatment of rheumatic arthritis, the ankiloziruyushchy spondilit, psoriatichesky arthritis, psoriasis, a disease.

EGIS-RUS LLC (affiliated enterprise EGIS Pharmaceutical Plant Ltd), the Russian biopharmaceutical company "Nanolek" and South Korean biopharmaceutical company "Celltrion" announced the intention on September 8, 2015 at the International exhibition "CPhI Korea – 2015 in Seoul. On the basis of the agreement, the parties agreed about start of local production of biosimilar medicine infliksimab – Flammegis on the Russian production site of biopharmaceutical company "Nanolek". Agreement signature took place at the stand of the Ministry of Industry and Trade of the Russian Federation in the presence of the Deputy Minister of Industry and Trade of the Russian Federation Sergey Tsyba and representatives of the Korean association of representatives of the biomedical industry (KoBIA).

The number of the patients in the world having rheumatoid arthritis increases from year to year and already reached 21 million people. In Russia the total quantity of patients with rheumatoid arthritis makes about one million people. Monoclonal antibodies made this break in fight against diseases of cancer and autoimmune frustration, promoting improvement of quality of life of once incurable patients. When performing the international multicenter clinical trials, the medicine Flammegis® showed the clinical equivalence and security when comparing with an original infliksimab of Remicade®. Agreement parties are sure that as a result of their cooperation the Russian doctors and patients will get access to modern medicamentous therapy by the latest biosimilar Flammegis® medicine.

Earlier it was reported that at the beginning of 2010 the Egis company signed the agreement on cooperation with South Korean biopharmaceutical company "Celltrion", having acquired exclusive rights on marketing and distribution of 8 biosimilar medicines in Russia and 4 CIS countries and also a floor exclusive rights on distribution of medicines in 12 more European Union countries.

The biological analog of medicine infliksimab – the first product specified in this agreement is registered in Russia under a trade name of Flammegis® (in EU countries medicine is registered on TM Remsima®).

By the end of 2015 localization process of medicine enters the final phase: medicine will be ready to be produced according to international standards of biopharmaceutical production. The final stage of localization plans start of a full stroke of production of the medicine Flammegis® on the production site of Nanolek in the Kirov region.